In fact, two biosimilars that inhibit ALK1, an monoclonal antibody and ALK1-Fc (extracellular domain of ALK1 fused with Fc fragment), have shown inhibitory effects on angiogenesis in animal tumor model and are currently used in phase I clinical trials [2]. This evidence concerns the gene ACVRL1 and neoplasm.